TScan Reorganizes Pipeline Priorities, Implements Workforce Reduction
I'm LongbridgeAI, I can summarize articles.TScan Therapeutics announced a major reorganization, reducing its workforce by approximately 75% to prioritize in vivo solid tumor TCR-T therapies. The company is shifting capital to lead oncology programs and pausing enrollment in the Phase 3 ALLOHA-2 hematologic malignancy study due to funding constraints. TScan aims to advance PRAME and MAGE-A4 candidates into IND-enabling studies, with preclinical data expected in Q1 2027. Shares dropped nearly 37% following the announcement.
TScan Therapeutics Inc. (NASDAQ:TCRX) on Wednesday announced a major corporate reorganization to prioritize its in vivo solid tumor pipeline, prompting a workforce reduction of approximately 75%.
The clinical-stage biotechnology company is shifting capital toward its lead oncology programs while pausing new enrollment in its Phase 3 ALLOHA-2 study for hematologic malignancies due to funding constraints.
Read Also: Silence Therapeutics Says Blood Cancer Trial Delivers 'Best-Case Outcome'
Advancing In Vivo Solid Tumor Therapies
The strategic pivot focuses TScan’s efforts on developing in vivo-engineered TCR-T therapies, starting as singleplexed treatments and ultimately expanding into multiplexed options.
The company advanced two product candidates targeting PRAME and MAGE-A4 into IND-enabling studies.
By leveraging an in vivo engineering method, TScan aims to bypass lymphodepletion requirements while overcoming the high manufacturing costs and delivery delays typical of ex vivo therapies.
Management plans to release preclinical data in the first quarter of 2027, submit its initial IND application in the third quarter of 2027, and initiate Phase 1 development in the fourth quarter of 2027.
Phase 1 ALLOHA Trial Results and Strategic Pause
Capital constraints led TScan to pause enrollment in the Phase 3 ALLOHA-2 trial for TSC-101.
The business will continue tracking seven enrolled treatment-arm patients alongside 13 Cohort C patients from the Phase 1 ALLOHA trial at reduced costs.
In earlier Cohort A data, TSC-101 demonstrated durable remissions and lower relapse rates versus controls.
Recent Cohort C data revealed complete donor chimerism across all 13 tracked patients, including two who converted after receiving a third TSC-101 infusion or targeted agents.
Observed adverse events remained consistent with standard post-transplant profiles.
Preserving Value Through Strategic Partnerships
TScan expects to publish updated Cohort C data in the fourth quarter of 2026 and commercial-ready manufacturing process data in the second quarter of 2027.
The company intends to pursue strategic partnerships to preserve potential value across its heme and autoimmune programs.
TCRX Stock Price Activity: TScan Therapeutics shares were down 36.95% at 42 cents at the time of publication on Wednesday, according to Benzinga Pro data.
Photo: Billion Photos / Shutterstock
Read Also: Ed Yardeni Rejects Bond Panic, Says Dalio and Dimon Are Too 'Pessimistic'